Logo image of NOVC.DE

(NOVC.DE) Stock Price, Quote, News and Overview

FRA:NOVC - Deutsche Boerse Ag - DK0060534915 - Common Stock - Currency: EUR

86.34  -2.03 (-2.3%)

NOVC.DE Quote, Performance and Key Statistics

FRA:NOVC (9/19/2023, 5:26:42 PM)

86.34

-2.03 (-2.3%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High185.12
52 Week Low85.56
Market Cap386.28B
Shares4.47B
Float1.58B
Yearly DividendN/A
Dividend YieldN/A
PE43.17
Fwd PE15.13
Earnings (Next)N/A N/A
IPO05-17 1974-05-17


NOVC.DE short term performance overview.The bars show the price performance of NOVC.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

NOVC.DE long term performance overview.The bars show the price performance of NOVC.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -2 -4 -6 -8 -10

The current stock price of NOVC.DE is 86.34 EUR. In the past month the price decreased by -49.3%. In the past year, price decreased by -13.99%.

 / NOVC Daily stock chart

NOVC.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
LLY.DE ELI LILLY & CO 67.38 794.44B
1LLY.MI ELI LILLY & CO 67.23 792.68B
ZEG.DE ASTRAZENECA PLC 20.75 440.83B
NOV.DE NOVO NORDISK A/S-B 27.77 377.28B
JNJ.DE JOHNSON & JOHNSON 16.23 373.18B
1JNJ.MI JOHNSON & JOHNSON 15.99 367.60B
SAN.PA SANOFI 13.58 261.40B
SNW.DE SANOFI 13.56 261.10B
1SAN.MI SANOFI 13.55 260.85B
6MK.DE MERCK & CO. INC. 11.64 215.02B
1MRKX.MI MERCK & CO. INC. 11.12 205.41B
PFE.DE PFIZER INC 8.49 142.86B

About NOVC.DE

Company Profile

NOVC logo image Novo Nordisk A/S is a DK-based company operating in Pharmaceuticals industry. Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

Novo Alle 1

Bagsvaerd DK

Employees: 59337

Company Website: https://www.novonordisk.com/

Phone: 4544448888.0

/ NOVC.DE FAQ

What is the stock price of today?

The current stock price of NOVC.DE is 86.34 EUR. The price decreased by -2.3% in the last trading session.


What is the ticker symbol for stock?

The exchange symbol of is NOVC and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is NOVC.DE stock listed?

NOVC.DE stock is listed on the Deutsche Boerse Ag exchange.


What is the price forecast or stock price prediction for stock?

32 analysts have analysed NOVC.DE and the average price target is 169.94 EUR. This implies a price increase of 96.83% is expected in the next year compared to the current price of 86.34. Check the stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is worth?

(NOVC.DE) has a market capitalization of 386.28B EUR. This makes NOVC.DE a Mega Cap stock.


How many employees does have?

(NOVC.DE) currently has 59337 employees.


Is (NOVC.DE) expected to grow?

The Revenue of (NOVC.DE) is expected to grow by 27.56% in the next year. Check the estimates tab for more information on the NOVC.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy (NOVC.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does (NOVC.DE) stock pay dividends?

NOVC.DE does not pay a dividend.


What is the Price/Earnings (PE) ratio of (NOVC.DE)?

The PE ratio for (NOVC.DE) is 43.17. This is based on the reported non-GAAP earnings per share of 2 and the current share price of 86.34 EUR. Check the full fundamental report for a full analysis of the valuation metrics for NOVC.DE.


NOVC.DE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

NOVC.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to NOVC.DE. NOVC.DE gets an excellent profitability rating and is at the same time showing great financial health properties.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NOVC.DE Financial Highlights

Over the last trailing twelve months NOVC.DE reported a non-GAAP Earnings per Share(EPS) of 2. The EPS decreased by -32.68% compared to the year before.


Industry RankSector Rank
PM (TTM) 33.4%
ROA 23.95%
ROE 74.32%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%-26.37%
Sales Q2Q%31.59%
EPS 1Y (TTM)-32.68%
Revenue 1Y (TTM)28.03%

NOVC.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 71% to NOVC.DE. The Buy consensus is the average rating of analysts ratings from 32 analysts.

For the next year, analysts expect an EPS growth of 96.77% and a revenue growth 27.56% for NOVC.DE


Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts70.63
Price Target169.94 (96.83%)
EPS Next Y96.77%
Revenue Next Year27.56%